RxDoctor Payments Data

Madhusudhan Pamganamamula, MD

Internal Medicine · Odessa, TXNPI 1699743187

Payments from drug & device makers

$71,485in general payments, 2019–2025

Across 128 payments — averaging $558.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$41K
  • Amgen$27K
  • Biohaven Pharmaceuticals, Inc.$2K
  • AbbVie$526
  • Astellas Pharma US Inc$195
  • Novo Nordisk$172
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$1,20016%
  • Speaking & faculty fees$4,11353%
  • Travel & lodging$3965%
  • Food & beverage$1,75623%
  • Education$2303%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,485 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$293,022
Medicare patients
194
Services billed
12,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$137,139
OzempicSemaglutide133$131,876
EliquisApixaban68$73,412
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog54$48,693
Soliqua 100-33Insulin Glargine/Lixisenatide35$39,463
Tresiba Flextouch U-200Insulin Degludec19$28,897
XareltoRivaroxaban14$21,209
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$17,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,351
JardianceEmpagliflozin14$15,534
EntrestoSacubitril/Valsartan17$15,250
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,849
JanuviaSitagliptin Phosphate14$14,275
LinzessLinaclotide16$12,232
Repatha SureclickEvolocumab17$9,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$38$137,13997 claims
Novo NordiskOzempic$172$131,876133 claims
PfizerEliquis$102$73,41268 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$20$39,46335 claims
GSKTrelegy Ellipta, Shingrix$103$20,55335 claims
NovartisEntresto$166$15,25017 claims
AstraZenecaBreztri Aerosphere$92$14,84915 claims
AbbVieLinzess$526$12,23216 claims
Astellas Pharma US IncMyrbetriq$195$9,84511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →